Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech's just-launched pivotal trial for its rare disease candidate. Nextech and EQT Life Sciences co-led the charge, with participation from Sanofi, Mubadala Capital, OrbiMed, Blue Owl Capital and RA Capital Management, among others.